Results 151 to 160 of about 2,835 (182)

Filgotinib as rheumatoid arthritis therapy

Drugs of Today, 2021
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and progressive disability when inflammation cannot be sufficiently controlled. Despite treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biological DMARDs (bDMARDs), up to 30% of RA patients do not reach or fail to ...
A, Becciolini, E, Di Donato, D, Santilli, G, Lucchini, F, Mozzani, M, Riva, A, Ariani   +6 more
openaire   +2 more sources

Filgotinib in rheumatoid arthritis

Expert Review of Clinical Immunology, 2022
Rheumatoid Arthritis (RA) remains a challenge for rheumatologists and patients despite implementation of intensive treat-to-target strategies in shared decision with patients and an increasing availability of drugs. Janus kinase inhibitors (JAKi) are a new generation of oral targeted drugs. Filgotinib preferentially inhibits JAK1 and is the latest JAKi
openaire   +2 more sources

Filgotinib

Reactions Weekly
  +9 more sources

Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights

Expert Review of Clinical Pharmacology, 2021
Rheumatoid arthritis (RA) is a chronic autoimmune disease, whose natural course has been deeply modified thanks to the development of new therapeutic approaches. The Janus kinase inhibitors (Jakinibs) represent the newest class of drugs introduced for treating RA.
Maria Gabriella Raimondo, Martina Biggioggero, Lavinia Agra Coletto, Andreas Ramming, Roberto Caporali, Ennio Giulio Favalli   +5 more
openaire   +2 more sources

Distinct trajectories of symptomatic response in ulcerative colitis during filgotinib therapy: A post hoc analysis from the SELECTION study [PDF]

United European Gastroenterology Journal
peer reviewedBACKGROUND: Filgotinib is an oral, once-daily, Janus kinase 1 preferential inhibitor approved for treatment of ulcerative colitis (UC) following the phase 2b/3 SELECTION trial.
Tadakazu Hisamatsu, Edouard Louis, Haridarshan Patel   +2 more
exaly   +2 more sources

Filgotinib for the Treatment of Refractory Collagenous Colitis

Journal of Crohn's and Colitis, 2023
Tomoyoshi Shibuya, Akihito Nagahara
openaire   +2 more sources

Filgotinib for ulcerative colitis

Nature Reviews Gastroenterology & Hepatology, 2021
openaire   +2 more sources

Filgotinib/prednisolone

Reactions Weekly, 2023
openaire   +1 more source

Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1)

Modern Rheumatology, 2022
Tatsuya Atsumi, Edward Keystone, Yoshiya Tanaka   +2 more
exaly  

Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis

Journal of Crohn's and Colitis, 2022
Silvio Danese, Joana Roseira, Ferdinando D'Amico   +2 more
exaly